Severity | Reason for Immunocompromise | Core condition/state | Immunosuppressive medication or treatment | Patients (n) | ||
---|---|---|---|---|---|---|
Severe (N = 48) | Primary Immunodeficiency [19] | Combined Variable Immune Deficiency | NA | 1 | 4 | |
CD4/CD8 idiopathic lymphocytopenia | 1 | |||||
Undefined primary immune deficiency | 1 | |||||
CD4 T lymphocyte deficiency | 1 | |||||
Malignancy | Haematological Cancer | Myeloproliferative Neoplasm: POEMS Syndrome (Castleman Variant) | HSCT < 24 months [7] | 1 | 20 | |
Non-Hodgkin’s Lymphoma: High grade relapsed follicular lymphoma | 1 | |||||
Non-Hodgkin’s Lymphoma: Diffuse large B-cell lymphoma | 2 | |||||
Hodgkin’s Lymphoma | 2 | |||||
ALL (Acute lymphoblastic leukaemia) | 1 | |||||
Non-Hodgkin’s Lymphoma | HSCT > 24 months plus GVHD [18] | 1 | ||||
ALL (acute lymphoblastic leukaemia) | 1 | |||||
ALL (Acute lymphoid leukaemia) | < 24 months after CAR-T therapy, IT MTX low dose [7] | 1 | ||||
Non-Hodgkin’s (Follicular lymphoma) | 3 | |||||
Non-Hodgkin’s (MALT-lymphoma) | 1 | |||||
Non-Hodgkin’s lymphoma | IT MTX (low dose) [18] | 1 | ||||
Chronic lymphoproliferative disorder: Chronic Myeloid Leukaemia [18] | 1 | |||||
Chronic Lymphoproliferative disorder: CLL (chronic lymphocytic leukaemia) [18] | NA | 1 | ||||
Non-Hodgkin’s: T-Lymphoblastic Lymphoma | Maintenance vincristine, methotrexate > 25 mg weekly, mercaptopurine > 1.5 mg/Kg/day [26] | 1 | ||||
Myeloproliferative disease: Waldenström macroglobulinaemia [18] | NA | 1 | ||||
Myeloproliferative neoplasm Polycythaemia rubra vera | Peginterferon alfa-2a [52] | 1 | ||||
Immune Modulated Conditions on significant dose immunosuppression | SOT | Renal transplant | Tacrolimus, sirolimus [7] | 2 | 22 | |
Rheumatological Conditions | Rheumatoid arthritis | TNF inhibitors [19] | 2 | |||
Juvenile arthritis | 3 | |||||
Sacroiliitis | 1 | |||||
Enthesitis related arthritis/uveitis | 1 | |||||
Rheumatoid arthritis | Rituximab < 6 months [19] | 1 | ||||
Primary Sjogren’s syndrome | MMF > 1 g a day [7] | 1 | ||||
SRP-positive polymyositis | MMF/calcineurin inhibitors/steroids [7] | 1 | ||||
Juvenile Arthritis | Co-stimulation modulator Abatacept [51] | 1 | ||||
Rheumatoid arthritis | Anti-IL-6 agent tocilizumab [7] | 1 | ||||
Psoriatic arthritis | 1 | |||||
Neurological | Multiple sclerosis | 1 | ||||
2 | ||||||
Fingolimod [7] | 1 | |||||
Gastroenterological | Crohn’s disease | 1 | ||||
1 | ||||||
Ophthalmological | Chorioretinitis (clinically active) | MMF > 1 g/day [7] | 1 | |||
Thymic Dysfunction | Myasthenia Gravis | Thymectomy [55] | 2 | 2 |